The path to the standardization of PTH: Is this a realistic possibility? a position paper of the IFCC C-BM

Etienne Cavalier*, Samuel Vasikaran, Harjit P. Bhattoa, Annemieke C. Heijboer, Konstantinos Makris, Candice Z. Ulmer

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Parathyroid hormone (PTH) determination is of greatest importance for patients suffering from parathyroid gland disorders and for the follow-up of bone turnover in patients suffering from chronic kidney disease (CKD). Two generations of PTH assays are simultaneously present on the market for PTH quantification. As these assays are not yet standardized, this results in a significant level of confusion in the care of CKD patients. One key objective of the IFCC Committee for Bone Metabolism is to improve this situation. In this position paper, we will highlight the current state of PTH testing and propose a pathway to ultimately overcome issues resulting from PTH assay variability.

Original languageEnglish
Pages (from-to)44-51
Number of pages8
JournalClinica Chimica Acta
Volume515
DOIs
Publication statusPublished - Apr 2021

Cite this